Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals' stock price has been impacted by several key events in the past six months. In Q1 2025, Ionis reported increased revenue and raised its full-year guidance. In Q3 2025, the company reported a quarterly loss but beat estimates and increased its full-year revenue guidance. The launch of TRYNGOLZA has driven revenue growth. DAWNZERA received a positive opinion from the European Medicines Agency. Phase 3 data for olezarsen in severe hypertriglyceridemia led to a stock dip. Ionis announced a convertible senior notes offering. Arrowhead Pharmaceuticals filed a patent complaint against Ionis. Insiders have sold shares of company stock. The stock has seen a significant increase over the last six months and year.

There is no explicit indication of significant demand seasonality for Ionis Pharmaceuticals' products and services. Revenue growth is driven by new product launches, royalties, and pipeline advancements, rather than seasonal fluctuations. Demand for essential medicines is typically more stable and less subject to seasonal patterns.

Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in RNA-targeted drugs, founded in 1989 and headquartered in Carlsbad, California. Ionis operates within the Health Technology sector, pioneering antisense therapy, RNA interference, and CRISPR therapeutics. The company sells its own medicines and generates revenue from partnered drugs. Ionis focuses on medicines for genetic diseases, neurological disorders, cardiovascular diseases, and cancer. Major products include TRYNGOLZA for familial chylomicronemia syndrome, WAINUA for polyneuropathy, SPINRAZA for spinal muscular atrophy, QALSODY for amyotrophic lateral sclerosis, TEGSEDI for polyneuropathy, WAYLIVRA for FCS, and DAWNZERA for hereditary angioedema.

Ionis Pharmaceuticals, Inc. is headquartered in Carlsbad, California, U.S. The company sells its products in North America and Europe.

Ionis Pharmaceuticals has maintained a generally positive brand perception, driven by its advancements in RNA-targeted medicines and successful product launches. The company emphasizes its commitment to delivering life-changing medicines. Patent litigation with Arrowhead Pharmaceuticals involves allegations of patent infringement, but there is no significant negative impact on Ionis' overall brand reputation.

Ionis Pharmaceuticals, Inc. stock is predominantly owned by institutional investors, holding over 90% of the outstanding shares. Major institutional owners include Fmr LLC, Vanguard Group Inc, T. Rowe Price Investment Management Inc, Capital World Investors and BlackRock Institutional Trust Company, N.A.. Individual insider ownership accounts for 2.60% of the company's stock. Eli Lilly Co is a significant individual shareholder.